Business Strategy

Vybion is a development stage biopharmaceutical company with a leading human monoclonal antibody development platform, called ProCode, and an in-licensed antibody drug, called CoFab, for an unmet market need with no existing competition. The Company is developing a novel pipeline of drugs based on antibody and antibody fragments. Our business strategy is to achieve value creation with exit opportunities at multiple value inflection points within 3-4 years while building an integrated clinical stage company capable of bringing products to market through partnerships.